The current report on the IP legal and regulatory framework and access to medicines in Mozambique is a follow-up analysis based on the 2021 report. An innovative element in this new report is the fact that it adds reflections on the role that different stakeholders can play to improve access to medicines in Mozambique.
Some of the recommendations include the need, from the Ministry of Health, to include Lenacapavir and Cabotegravir in the list of essential medicines for HIV treatment and improve conditions for storage, conservation and transportation of medicines, generally, and specifically for HIV and TB treatment. The Parliament and IP department should review the IP legal and regulatory framework to incorporate all available TRIPS flexibilities and refer to the term “essential medicines” in the legal definition of “public interest” embedded in the IP law to meet compulsory licensing threshold for HIV and TB treatment. CSOs should, amongst others, raise awareness, lobby and support Parliament on legislative and regulatory reforms speaking to IP and access to medicines. The kind of support provided to the Parliament may include IP training on IP law and access to medicines as well as provision of information needed for the Parliament to exercise effective oversight on government on challenges/ progress speaking to aspects related to IP law and access to medicines.